|
Oct 30
|
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
|
|
Sep 30
|
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
|
|
Sep 27
|
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
|
|
May 11
|
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
|
|
May 9
|
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
|
May 8
|
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
|
|
Apr 9
|
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
|
|
Apr 3
|
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
|
|
Mar 25
|
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
|
|
Mar 23
|
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
|
|
Mar 4
|
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|
|
Nov 27
|
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
|
|
Nov 3
|
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
|
|
Nov 2
|
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 31
|
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
|
|
Aug 30
|
2 ‘Strong Buy’ Stocks Under $10 That Oppenheimer Sees Surging Over 200% — Here’s Why They Could Jump
|
|
Aug 25
|
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
|